

SHE THOUGHT
HER DEPRESSION
SYMPTOMS
WOULD NEVER
GET BETTER



THE FIRST AND ONLY NMDA RECEPTOR ANTAGONIST
APPROVED IN CONJUNCTION WITH AN ORAL
ANTIDEPRESSANT FOR TREATMENT-RESISTANT
DEPRESSION (TRD) IN ADULTS.¹

A NEW DAY BEGINS
WITH SPRAVATO™

Learn more at SPRAVATOHCP.com.

Device as shown does not depict actual position
for administration.

Indication

SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

Important Safety Information

**WARNING: SEDATION, DISSOCIATION; ABUSE AND MISUSE;
and SUICIDAL THOUGHTS AND BEHAVIORS**

See full prescribing information for complete boxed warning

- Risk for sedation and dissociation after administration. Monitor patients for at least two hours after administration (5.1, 5.2).
- Potential for abuse and misuse. Consider the risks and benefits of using SPRAVATO™ prior to use in patients at higher risk of abuse. Monitor for signs and symptoms of abuse and misuse (5.3).
- SPRAVATO™ is only available through a restricted program called the SPRAVATO™ REMS (5.4).
- Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO™ is not approved for use in pediatric patients (5.5).

CONTRAINDICATIONS

SPRAVATO™ is contraindicated in patients with:

- Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation
- History of intracerebral hemorrhage
- Hypersensitivity to esketamine, ketamine, or any of the excipients

NMDA=N-methyl-D-aspartate.

Reference: 1. SPRAVATO™ [Prescribing Information].
Titusville, NJ: Janssen Pharmaceuticals, Inc. May 2019.

WARNINGS AND PRECAUTIONS

Sedation: In clinical trials, 49% to 61% of SPRAVATO™-treated patients developed sedation and 0.3% of SPRAVATO™-treated patients experienced loss of consciousness.

Because of the possibility of delayed or prolonged sedation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.

Closely monitor for sedation with concomitant use of SPRAVATO™ with CNS depressants [see Drug Interaction (7.1)].

SPRAVATO™ is available only through a restricted program under a REMS.

Dissociation: The most common psychological effects of SPRAVATO™ were dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization (61% to 75% of SPRAVATO™-treated patients developed dissociative or perceptual changes). Given its potential to induce dissociative effects, carefully assess patients with psychosis before administering SPRAVATO™; treatment should be initiated only if the benefit outweighs the risk.

Because of the risks of dissociation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.

SPRAVATO™ is available only through a restricted program under a REMS.

Abuse and Misuse: SPRAVATO™ contains esketamine, a Schedule III controlled substance (CIII), and may be subject to abuse and diversion. Assess each patient's risk for abuse or misuse prior to prescribing and monitor all patients for the development of these behaviors or conditions, including drug-seeking behavior, while on therapy. Individuals with a history of drug abuse or dependence are at greater risk; therefore, use careful consideration prior to treatment of individuals with a history of substance use disorder and monitor for signs of abuse or dependence.

SPRAVATO™ is available only through a restricted program under a REMS.

Please see additional Important Safety Information and Brief Summary of full Prescribing Information, including Boxed WARNINGS, on following pages.

Important Safety Information (continued)

SPRAVATO™ Risk Evaluation and Mitigation Strategy (REMS): SPRAVATO™ is available only through a restricted program called the SPRAVATO™ REMS because of the risks of serious adverse outcomes from sedation, dissociation, and abuse and misuse.

Important requirements of the SPRAVATO™ REMS include the following:

- Healthcare settings must be certified in the program and ensure that SPRAVATO™ is:
 - Only dispensed in healthcare settings and administered to patients who are enrolled in the program.
 - Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO™.
- Pharmacies must be certified in the REMS and must only dispense SPRAVATO™ to healthcare settings that are certified in the program.

Further information, including a list of certified pharmacies, is available at www.SPRAVATOREMS.com or 1-855-382-6022.

Suicidal Thoughts and Behaviors in Adolescents and Young Adults: In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included adult and pediatric patients, the incidence of suicidal thoughts and behaviors in patients age 24 years and younger was greater than in placebo-treated patients. SPRAVATO™ is not approved in pediatric (<18 years of age) patients.

There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied.

Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing SPRAVATO™ and/or the concomitant oral antidepressant, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

Increase in Blood Pressure: SPRAVATO™ causes increases in systolic and/or diastolic blood pressure (BP) at all recommended dosages. Increases in BP peak approximately 40 minutes after SPRAVATO™ administration and last approximately 4 hours.

Approximately 8% to 17% of SPRAVATO™-treated patients experienced an increase of more than 40 mmHg in systolic BP and/or 25 mmHg in diastolic BP in the first 1.5 hours after administration at least once during the first 4 weeks of treatment.

A substantial increase in blood pressure could occur after any dose administered even if smaller blood pressure effects were observed with previous administrations. SPRAVATO™ is contraindicated in patients for whom an increase in BP or intracranial pressure poses a serious risk (e.g., aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage). Before prescribing, patients with other cardiovascular and cerebrovascular conditions should be carefully assessed to determine whether the potential benefits of SPRAVATO™ outweigh its risk.

Assess BP prior to administration of SPRAVATO™. In patients whose BP is elevated prior to SPRAVATO™ administration (as a general guide: >140/90 mmHg), a decision to delay SPRAVATO™ therapy should be taken into account to balance the benefit and risk in individual patients.

BP should be monitored for at least 2 hours after SPRAVATO™ administration. Measure blood pressure around 40 minutes post-dose and subsequently as clinically warranted until values decline. If BP remains high, promptly seek assistance from practitioners experienced in BP management. Refer patients experiencing symptoms of a hypertensive crisis (e.g., chest pain, shortness of breath) or hypertensive encephalopathy (e.g., sudden severe headache, visual disturbances, seizures, diminished consciousness or focal neurological deficits) immediately for emergency care.

Closely monitor blood pressure with concomitant use of SPRAVATO™ with psychostimulants or monoamine oxidase inhibitors (MAOIs) [see Drug Interactions (7.2, 7.3)].

In patients with history of hypertensive encephalopathy, more intensive monitoring, including more frequent blood pressure and symptom assessment, is warranted because these patients are at increased risk for developing encephalopathy with even small increases in blood pressure.

Cognitive Impairment

Short-Term Cognitive Impairment: In a study in healthy volunteers, a single dose of SPRAVATO™ caused cognitive performance decline 40 minutes post-dose. SPRAVATO™-treated subjects required a greater effort to complete the cognitive tests at 40 minutes post-dose. Cognitive performance and mental effort were comparable between SPRAVATO™ and placebo at 2 hours post-dose. Sleepiness was comparable after 4 hours post-dose.

Long-Term Cognitive Impairment: Long-term cognitive and memory impairment have been reported with repeated ketamine misuse or abuse. No adverse effects of SPRAVATO™ nasal spray on cognitive functioning were observed in a one-year open-label safety study; however, the long-term cognitive effects of SPRAVATO™ have not been evaluated beyond one year.

Impaired Ability to Drive and Operate Machinery: Before SPRAVATO™ administration, instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day following a restful sleep. Patients will need to arrange transportation home following treatment with SPRAVATO™.

Ulcerative or Interstitial Cystitis: Cases of ulcerative or interstitial cystitis have been reported in individuals with long-term off-label use or misuse/abuse of ketamine. In clinical studies with SPRAVATO™ nasal spray, there was a higher rate of lower urinary tract symptoms (pollakiuria, dysuria, micturition urgency, nocturia, and cystitis) in SPRAVATO™-treated patients than in placebo-treated patients. No cases of esketamine-related interstitial cystitis were observed in any of the studies, which involved treatment for up to a year.

Monitor for urinary tract and bladder symptoms during the course of treatment with SPRAVATO™ and refer to an appropriate healthcare provider as clinically warranted.

Embryo-fetal Toxicity: SPRAVATO™ may cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to an infant exposed to SPRAVATO™ *in utero*. Advise women of reproductive potential to consider pregnancy planning and prevention.

DRUG INTERACTIONS

CNS depressants (e.g., benzodiazepines, opioids, alcohol): Concomitant use may increase sedation. Closely monitor for sedation with concomitant use of CNS depressants.

Psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil): Concomitant use may increase blood pressure. Closely monitor blood pressure with concomitant use of psychostimulants.

Monoamine oxidase inhibitors (MAOIs): Concomitant use may increase blood pressure. Closely monitor blood pressure with concomitant use of MAOIs.

USE IN SPECIFIC POPULATIONS

Pregnancy: SPRAVATO™ is not recommended during pregnancy. SPRAVATO™ may cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to an infant exposed to SPRAVATO™ *in utero*. There are risks to the mother associated with untreated depression in pregnancy. If a woman becomes pregnant while being treated with SPRAVATO™, treatment with SPRAVATO™ should be discontinued and the patient should be counseled about the potential risk to the fetus.

Pregnancy Exposure Registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including SPRAVATO™, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at <https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/>.

Lactation: SPRAVATO™ is present in human milk. Because of the potential for neurotoxicity, advise patients that breastfeeding is not recommended during treatment with SPRAVATO™.

Females and Males of Reproductive Potential: SPRAVATO™ may cause embryo-fetal harm when administered to a pregnant woman. Consider pregnancy planning and prevention for females of reproductive potential during treatment with SPRAVATO™.

Pediatric Use: The safety and effectiveness of SPRAVATO™ in pediatric patients have not been established.

Geriatric Use: Of the total number of patients in Phase 3 clinical studies exposed to SPRAVATO™, 12% were 65 years of age and older, and 2% were 75 years of age and older. No overall differences in the safety profile were observed between patients 65 years of age and older and patients younger than 65 years of age.

The mean esketamine C_{max} and AUC values were higher in elderly patients compared with younger adult patients.

The treatment of TRD in geriatric patients was evaluated in a 4-week, randomized, double-blind study comparing flexibly-dosed intranasal SPRAVATO™ plus a newly initiated oral antidepressant compared to intranasal placebo plus a newly initiated oral antidepressant in patients ≥65 years of age. At the end of four weeks, there was no statistically significant difference between groups on the primary efficacy endpoint of change from baseline to Week 4 on the Montgomery-Åsberg Depression Rating Scale (MADRS).

Hepatic Impairment: SPRAVATO™-treated patients with moderate hepatic impairment may need to be monitored for adverse reactions for a longer period of time.

SPRAVATO™ has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Use in this population is not recommended.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: SPRAVATO™ contains esketamine hydrochloride, the (S)-enantiomer of ketamine and a Schedule III controlled substance under the Controlled Substances Act.

Abuse: Individuals with a history of drug abuse or dependence may be at greater risk for abuse and misuse of SPRAVATO™. Abuse is the intentional, non-therapeutic use of a drug, even once, for its psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Careful consideration is advised prior to use of individuals with a history of substance use disorder, including alcohol.

SPRAVATO™ may produce a variety of symptoms including anxiety, dysphoria, disorientation, insomnia, flashback, hallucinations, and feelings of floating, detachment and to be “spaced out.” Monitoring for signs of abuse and misuse is recommended.

ADVERSE REACTIONS

The most common adverse reactions with SPRAVATO™ plus oral AD (incidence ≥5% and at least twice that of placebo nasal spray plus oral AD) were dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, blood pressure increased, vomiting, and feeling drunk.

Please see Brief Summary of full Prescribing Information, including Boxed WARNINGS, on following pages.

Janssen Neuroscience

PHARMACEUTICAL COMPANIES OF 

SPRAVATO®

(esketamine) nasal spray, CIII

Brief Summary

BEFORE PRESCRIBING SPRAVATO®, PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

WARNING: SEDATION; DISSOCIATION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS

Sedation

- Patients are at risk for sedation after administration of SPRAVATO [see *Warnings and Precautions*].

Dissociation

- Patients are at risk for dissociative or perceptual changes after administration of SPRAVATO [see *Warnings and Precautions*].

Because of the risks of sedation and dissociation, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting [see *Warnings and Precautions*].

Abuse and Misuse

- SPRAVATO has the potential to be abused and misused. Consider the risks and benefits of prescribing SPRAVATO prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse [see *Warnings and Precautions*].

Because of the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS [see *Warnings and Precautions*].

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients [see *Warnings and Precautions*].

INDICATIONS AND USAGE

SPRAVATO® is indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults [see *Clinical Studies (14.1) in Full Prescribing Information*].

Limitations of Use:

SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.

CONTRAINDICATIONS

SPRAVATO is contraindicated in patients with:

- Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation [see *Warnings and Precautions*]
- History of intracerebral hemorrhage [see *Warnings and Precautions*]
- Hypersensitivity to esketamine, ketamine, or any of the excipients.

WARNINGS AND PRECAUTIONS

Sedation

In clinical trials, 49% to 61% of SPRAVATO-treated patients developed sedation based on the Modified Observer's Alertness/Sedation scale (MOAA/s) [see *Adverse Reactions*], and 0.3% of SPRAVATO-treated patients experienced loss of consciousness (MOAA/s score of 0).

Because of the possibility of delayed or prolonged sedation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting [see *Dosage and Administration (2.4) in Full Prescribing Information*].

Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants [see *Drug Interaction*].

SPRAVATO is available only through a restricted program under a REMS [see *Warnings and Precautions*].

Dissociation

The most common psychological effects of SPRAVATO were dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization (61% to 75% of SPRAVATO-treated patients developed dissociative or perceptual changes based on the Clinician Administered Dissociative Symptoms Scale) [see *Adverse Reactions*]. Given its potential to induce dissociative effects, carefully assess patients with psychosis before administering SPRAVATO; treatment should be initiated only if the benefit outweighs the risk.

Because of the risks of dissociation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting [see *Dosage and Administration (2.4) in Full Prescribing Information*].

SPRAVATO® (esketamine) nasal spray, CIII

SPRAVATO is available only through a restricted program under a REMS [see *Warnings and Precautions*].

Abuse and Misuse

SPRAVATO contains esketamine, a Schedule III controlled substance (CIII), and may be subject to abuse and diversion. Assess each patient's risk for abuse or misuse prior to prescribing SPRAVATO and monitor all patients receiving SPRAVATO for the development of these behaviors or conditions, including drug-seeking behavior, while on therapy. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of SPRAVATO. Individuals with a history of drug abuse or dependence are at greater risk; therefore, use careful consideration prior to treatment of individuals with a history of substance use disorder and monitor for signs of abuse or dependence. [see *Drug Abuse and Dependence*].

SPRAVATO is available only through a restricted program under a REMS [see *Warnings and Precautions*].

SPRAVATO Risk Evaluation and Mitigation Strategy (REMS)

SPRAVATO is available only through a restricted program under a REMS called the SPRAVATO REMS because of the risks of serious adverse outcomes from sedation, dissociation, and abuse and misuse [see *Boxed Warning and Warnings and Precautions*].

Important requirements of the SPRAVATO REMS include the following:

- Healthcare settings must be certified in the program and ensure that SPRAVATO is:
 - Only dispensed in healthcare settings and administered to patients who are enrolled in the program.
 - Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO [see *Dosage and Administration (2.4) in Full Prescribing Information*].
- Pharmacies must be certified in the REMS and must only dispense SPRAVATO to healthcare settings that are certified in the program.

Further information, including a list of certified pharmacies is available at www.SPRAVATOREMS.com or 1-855-382-6022.

Suicidal Thoughts and Behaviors in Adolescents and Young Adults

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients (SPRAVATO is not approved in pediatric patients), the incidence of suicidal thoughts and behaviors in patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD). The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.

Table 1: Risk Differences of the Number of Patients with Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric* and Adult Patients

Age Range (Years)	Drug-Placebo Difference in Number of Patients with Suicidal Thoughts or Behaviors per 1000 Patients Treated
	Increases Compared to Placebo
<18	14 additional patients
18-24	5 additional patients
	Decreases Compared to Placebo
25-64	1 fewer patient
≥65	6 fewer patients

* SPRAVATO is not approved in pediatric patients.

It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.

Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing SPRAVATO and/or the concomitant oral antidepressant, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

Increase in Blood Pressure

SPRAVATO causes increases in systolic and/or diastolic blood pressure (BP) at all recommended doses. Increases in BP peak approximately 40 minutes after SPRAVATO administration and last approximately 4 hours [see *Adverse Reactions*].

Approximately 8% to 17% of SPRAVATO-treated patients and 1% to 3% of placebo-treated patients experienced an increase of more than 40 mmHg in systolic BP and/or 25 mmHg in diastolic BP in the first 1.5 hours after administration at least once during the first 4 weeks of treatment. A substantial increase in blood pressure could occur after any dose administered even if smaller blood pressure effects were observed with previous administrations. SPRAVATO is contraindicated in patients for whom an increase in BP or intracranial pressure poses a serious risk (e.g., aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage) [see *Contraindications*]. Before prescribing SPRAVATO, patients with other cardiovascular and cerebrovascular conditions should be carefully assessed to determine whether the potential benefits of SPRAVATO outweigh its risks.

Assess BP prior to administration of SPRAVATO. In patients whose BP is elevated prior to SPRAVATO administration (as a general guide: >140/90 mmHg) a decision to delay SPRAVATO therapy should take into account the balance of benefit and risk in individual patients.

BP should be monitored for at least 2 hours after SPRAVATO administration [see *Dosage and Administration (2.1, 2.4) in Full Prescribing Information*]. Measure blood pressure around 40 minutes post-dose and subsequently as clinically warranted until values decline. If BP remains high, promptly seek assistance from practitioners experienced in BP management. Refer patients experiencing symptoms of a hypertensive crisis (e.g., chest pain, shortness of breath) or hypertensive encephalopathy (e.g., sudden severe headache, visual disturbances, seizures, diminished consciousness or focal neurological deficits) immediately for emergency care.

Closely monitor blood pressure with concomitant use of SPRAVATO with psychostimulants or monoamine oxidase inhibitors (MAOIs) [see *Drug Interactions*].

In patients with history of hypertensive encephalopathy, more intensive monitoring, including more frequent blood pressure and symptom assessment, is warranted because these patients are at increased risk for developing encephalopathy with even small increases in blood pressure.

Cognitive Impairment**Short-Term Cognitive Impairment**

In a study in healthy volunteers, a single dose of SPRAVATO caused cognitive performance decline 40 minutes post-dose. Compared to placebo-treated subjects, SPRAVATO-treated subjects required a greater effort to complete cognitive tests at 40 minutes post-dose. Cognitive performance and mental effort were comparable between SPRAVATO and placebo at 2 hours post-dose. Sleepiness was comparable after 4 hours post-dose.

Long-Term Cognitive Impairment

Long-term cognitive and memory impairment have been reported with repeated ketamine misuse or abuse. No adverse effects of SPRAVATO nasal spray on cognitive functioning were observed in a one-year open-label safety study; however, the long-term cognitive effects of SPRAVATO have not been evaluated beyond one year.

Impaired Ability to Drive and Operate Machinery

Two placebo-controlled studies were conducted to assess the effects of SPRAVATO on the ability to drive [see *Clinical Studies (14.3) in Full Prescribing Information*]. The effects of SPRAVATO 84 mg were comparable to placebo at 6 hours and 18 hours post-dose. However, two SPRAVATO-treated subjects in one of the studies discontinued the driving test at 8 hours post-dose because of SPRAVATO-related adverse reactions.

Before SPRAVATO administration, instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day following a restful sleep. Patients will need to arrange transportation home following treatment with SPRAVATO.

Ulcerative or Interstitial Cystitis

Cases of ulcerative or interstitial cystitis have been reported in individuals with long-term off-label use or misuse/abuse of ketamine. In clinical studies with SPRAVATO nasal spray, there was a higher rate of lower urinary tract symptoms (pollakiuria, dysuria, micturition urgency, nocturia, and cystitis) in SPRAVATO-treated patients than in placebo-treated patients [see *Adverse Reactions*]. No cases of esketamine-related interstitial cystitis were observed in any of the studies, which included treatment for up to a year.

Monitor for urinary tract and bladder symptoms during the course of treatment with SPRAVATO, and refer to an appropriate healthcare provider as clinically warranted.

Embryo-fetal Toxicity

Based on published findings from pregnant animals treated with ketamine, the racemic mixture of arketamine and esketamine, SPRAVATO may cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to an infant exposed to SPRAVATO *in utero*. Advise women of reproductive potential to consider pregnancy planning and prevention [see *Use in Specific Populations*].

ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Sedation [see *Warnings and Precautions*]
- Dissociation [see *Warnings and Precautions*]
- Increase in Blood Pressure [see *Warnings and Precautions*]
- Cognitive Impairment [see *Warnings and Precautions*]
- Impaired Ability to Drive and Operate Machinery [see *Warnings and Precautions*]
- Ulcerative or Interstitial Cystitis [see *Warnings and Precautions*]
- Embryo-fetal Toxicity [see *Warnings and Precautions*]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Patient Exposure

SPRAVATO was evaluated for safety in 1709 patients diagnosed with treatment resistant depression (TRD) [see *Clinical Studies (14.1, 14.2) in Full Prescribing Information*] from five Phase 3 studies (3 short-term and 2 long-term studies) and one Phase 2 dose-ranging study. Of all SPRAVATO-treated patients in the completed Phase 3 studies, 479 (30%) received at least 6 months of treatment, and 178 (11%) received at least 12 months of treatment.

Adverse Reactions Leading to Discontinuation of Treatment

In short-term studies in adults < 65 years old (Study 1 pooled with another 4-week study), the proportion of patients who discontinued treatment because of an adverse reaction was 4.6% in patients who received SPRAVATO plus oral AD compared to 1.4% for patients who received placebo nasal spray plus oral AD. For adults ≥ 65 years old, the proportions were 5.6% and 3.1%, respectively. In Study 2, a long-term maintenance study, the discontinuation rates because of an adverse reaction were similar for patients receiving SPRAVATO plus oral AD and placebo nasal spray plus oral AD in the maintenance phase, at 2.6% and 2.1%, respectively. Across all Phase 3 studies, adverse reactions leading to SPRAVATO discontinuation in more than 2 patients were (in order of frequency): anxiety (1.2%), depression (0.9%), blood pressure increased (0.6%), dizziness (0.6%), suicidal ideation (0.5%), dissociation (0.4%), nausea (0.4%), vomiting (0.4%), headache (0.3%), muscular weakness (0.3%), vertigo (0.2%), hypertension (0.2%), panic attack (0.2%) and sedation (0.2%).

Most Common Adverse Reactions

The most commonly observed adverse reactions in TRD patients treated with SPRAVATO plus oral AD (incidence ≥5% and at least twice that of placebo nasal spray plus oral AD) were dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, blood pressure increased, vomiting, and feeling drunk. Table 2 shows the incidence of adverse reactions that occurred in TRD patients treated with SPRAVATO plus oral AD at any dose and greater than patients treated with placebo nasal spray plus oral AD.

Table 2: Adverse Reactions Occurring in ≥2% of TRD Patients Treated with SPRAVATO + Oral AD at Any Dose and at a Greater Rate than Patients Treated with Placebo Nasal Spray + Oral AD

	SPRAVATO + Oral AD (N=346)	Placebo + Oral AD (N=222)
Cardiac disorders		
Tachycardia*	6 (2%)	1 (0.5%)
Ear and labyrinth disorders		
Vertigo*	78 (23%)	6 (3%)
Gastrointestinal disorders		
Constipation	11 (3%)	3 (1%)
Diarrhea	23 (7%)	13 (6%)
Dry mouth	19 (5%)	7 (3%)
Nausea	98 (28%)	19 (9%)
Vomiting	32 (9%)	4 (2%)

Table 2: Adverse Reactions Occurring in ≥2% of TRD Patients Treated with SPRAVATO + Oral AD at Any Dose and at a Greater Rate than Patients Treated with Placebo Nasal Spray + Oral AD (continued)

	SPRAVATO + Oral AD (N=346)	Placebo + Oral AD (N=222)
General disorders and administration site conditions		
Feeling abnormal	12 (3%)	0 (0%)
Feeling drunk	19 (5%)	1 (0.5%)
Investigations		
Blood pressure increased*	36 (10%)	6 (3%)
Nervous system disorders		
Dizziness*	101 (29%)	17 (8%)
Dysarthria*	15 (4%)	0 (0%)
Dysgeusia*	66 (19%)	30 (14%)
Headache*	70 (20%)	38 (17%)
Hypoesthesia*	63 (18%)	5 (2%)
Lethargy*	37 (11%)	12 (5%)
Mental impairment	11 (3%)	2 (1%)
Sedation*	79 (23%)	21 (9%)
Tremor	12 (3%)	2 (1%)
Psychiatric disorders		
Anxiety*	45 (13%)	14 (6%)
Dissociation*	142 (41%)	21 (9%)
Euphoric mood	15 (4%)	2 (1%)
Insomnia	29 (8%)	16 (7%)
Renal and urinary disorders		
Pollakiuria	11 (3%)	1 (0.5%)
Respiratory, thoracic and mediastinal disorders		
Nasal discomfort*	23 (7%)	11 (5%)
Oropharyngeal pain	9 (3%)	5 (2%)
Throat irritation	23 (7%)	9 (4%)
Skin and subcutaneous tissue disorders		
Hyperhidrosis	14 (4%)	5 (2%)

* The following terms were combined:

Anxiety includes: agitation; anticipatory anxiety; anxiety; fear; feeling jittery; irritability; nervousness; panic attack; tension

Blood pressure increased includes: blood pressure diastolic increased; blood pressure increased; blood pressure systolic increased; hypertension

Dissociation includes: delusional perception; depersonalization/derealization disorder; derealization; diplopia; dissociation; dysesthesia; feeling cold; feeling hot; feeling of body temperature change; hallucination; hallucination, auditory; hallucination, visual; hyperacusis; illusion; ocular discomfort; oral dysesthesia; paresthesia; paresthesia oral; pharyngeal paresthesia; photophobia; time perception altered; tinnitus; vision blurred; visual impairment

Dizziness includes: dizziness; dizziness exertional; dizziness postural; procedural dizziness

Dysarthria includes: dysarthria; slow speech; speech disorder

Dysgeusia includes: dysgeusia; hypogeusia

Headache includes: headache; sinus headache

Hypoesthesia includes: hypoesthesia; hypoesthesia oral, hypoesthesia teeth, pharyngeal hypoesthesia

Lethargy includes: fatigue; lethargy

Nasal discomfort includes: nasal crusting; nasal discomfort; nasal dryness; nasal pruritus

Sedation includes: altered state of consciousness; hypersomnia; sedation; somnolence

Tachycardia includes: extrasystoles; heart rate increased; tachycardia

Vertigo includes: vertigo; vertigo positional

Sedation

Sedation was evaluated by adverse event reports and using the Modified Observer's Alertness/Sedation scale (MOAA/s). In the MOAA/s scale, 5 means "responds readily to name spoken in normal tone" and 0 means "no response after painful trapezius squeeze." Any decrease in MOAA/s

from pre-dose is considered to indicate presence of sedation, and such a decrease occurred in a higher number of patients on esketamine than placebo during the short-term trials (Table 3). Dose-related increases in the incidence of sedation were observed in a fixed-dose study [see *Warnings and Precautions*].

Table 3: Incidence of Sedation (MOAA/s <5) in Double-Blind, Randomized, Placebo-Controlled Fixed-Dose Study with Patients <65 Years of Age and Double-Blind, Randomized, Placebo-Controlled Flexible-Dose Study with Patients ≥65 years

	Patients <65 years		Patients ≥65 years		
	Placebo + Oral AD	SPRAVATO + Oral AD		Placebo + Oral AD	SPRAVATO + Oral AD
		56 mg	84 mg		
Number of patients*	N=112	N=114	N=114	N=63	N=72
Sedation (MOAA/s <5)	11%	50%	61%	19%	49%

*Patients who were evaluated with MOAA/s

Dissociation/Perceptual Changes

SPRAVATO can cause dissociative symptoms (including derealization and depersonalization) and perceptual changes (including distortion of time and space, and illusions). In clinical trials, dissociation was transient and occurred on the day of dosing. Dissociation was evaluated by adverse event reports and the Clinician-Administered Dissociative States Scale (CADSS) questionnaire. A CADSS total score of more than 4 indicates presence of dissociative symptoms, and such an increase to a score of 4 or more occurred in a higher number of patients on esketamine compared to placebo during the short-term trials (see Table 4). Dose-related increases in the incidence of dissociative symptoms (CADSS total score >4) were observed in a fixed-dose study. Table 4 shows the incidence of dissociation (CADSS total score >4) in a double-blind, randomized, placebo-controlled, fixed-dose study in adults <65 years of age and a double-blind, randomized, placebo-controlled, flexible-dose study with patients ≥ 65 years of age.

Table 4: Incidence of Dissociation (CADSS Total Score >4) in Double-Blind, Randomized, Placebo-Controlled Studies (Fixed-Dose Study with Patients <65 Years and Flexible-Dose Study with Patients ≥65 Years)

	Patients <65 years		Patients ≥65 years		
	Placebo + Oral AD	SPRAVATO + Oral AD		Placebo + Oral AD	SPRAVATO + Oral AD
		56 mg	84 mg		
Number of patients*	N=113	N=113	N=116	N=65	N=72
CADSS total score >4 and change >0	5%	61%	69%	12%	75%

* Number of patients who were evaluated with CADSS

Increase in Blood Pressure

The mean placebo-adjusted increases in systolic and diastolic blood pressure (SBP and DBP) over time were about 7 to 9 mmHg in SBP and 4 to 6 mmHg in DBP at 40 minutes post-dose and 2 to 5 mmHg in SBP and 1 to 3 mmHg in DBP at 1.5 hours post-dose in patients receiving SPRAVATO plus oral antidepressants (Table 5).

Table 5: Increases in Blood Pressure in Double-blind, Randomized-controlled, Short-term Trials of SPRAVATO + Oral AD Compared to Placebo Nasal Spray + Oral AD in the Treatment of TRD

	Patients <65 years		Patients ≥65 years	
	SPRAVATO + Oral AD N=346	Placebo + Oral AD N=222	SPRAVATO + Oral AD N=72	Placebo + Oral AD N=65
Systolic blood pressure				
≥180 mmHg	9 (3%)	---	2 (3%)	1 (2%)
≥40 mmHg increase	29 (8%)	1 (0.5%)	12 (17%)	1 (2%)
Diastolic blood pressure				
≥110 mmHg	13 (4%)	1 (0.5%)	---	---
≥25 mmHg increase	46 (13%)	6 (3%)	10 (14%)	2 (3%)

Nausea and Vomiting

SPRAVATO can cause nausea and vomiting (Table 6). Most of these events occurred on the day of dosing and resolved the same day, with the median duration not exceeding 1 hour in most subjects across dosing sessions. Rates of reported nausea and vomiting decreased over time across dosing sessions from the first week of treatment in the short-term studies, as well as over time with long-term treatment (Table 6).

Table 6: Incidence and Severity of Nausea and Vomiting in Double-blind, Randomized-controlled, Fixed-dose Study

Treatment (+ Oral AD)	N	Nausea		Vomiting	
		All	Severe	All	Severe
SPRAVATO 56 mg	115	31 (27%)	0	7 (6%)	0
SPRAVATO 84 mg	116	37 (32%)	4 (3%)	14 (12%)	3 (3%)
Placebo Nasal Spray	113	12 (11%)	0	2 (2%)	0

Sense of Smell

Sense of smell was assessed over time; no difference was observed between patients treated with SPRAVATO plus oral AD and those treated with placebo nasal spray plus oral AD during the double-blind maintenance phase of Study 2 [see *Clinical Studies (14.2) in Full Prescribing Information*].

DRUG INTERACTIONS**Central Nervous System Depressants**

Concomitant use with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation [see *Warnings and Precautions*]. Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants.

Psychostimulants

Concomitant use with psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) may increase blood pressure [see *Warnings and Precautions*]. Closely monitor blood pressure with concomitant use of SPRAVATO with psychostimulants.

Monoamine Oxidase Inhibitors (MAOIs)

Concomitant use with monoamine oxidase inhibitors (MAOIs) may increase blood pressure [see *Warnings and Precautions*]. Closely monitor blood pressure with concomitant use of SPRAVATO with MAOIs.

USE IN SPECIFIC POPULATIONS**Pregnancy**Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including SPRAVATO, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at <https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/>.

Risk Summary

SPRAVATO is not recommended during pregnancy. There are insufficient data on SPRAVATO use in pregnant women to draw conclusions about any drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Based on published findings from pregnant animals treated with ketamine, the racemic mixture of arketamine and esketamine, SPRAVATO may cause fetal harm when administered to pregnant women (see *Data*). Advise pregnant women of the potential risk to an infant exposed to SPRAVATO *in utero*. There are risks to the mother associated with untreated depression in pregnancy (see *Clinical Considerations*). If a woman becomes pregnant while being treated with SPRAVATO, treatment with esketamine should be discontinued and the patient should be counseled about the potential risk to the fetus.

Published studies in pregnant primates demonstrate that the administration of drugs that block N-methyl-D-aspartate (NMDA) receptors during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans [see *Use in Specific Populations*].

In an embryo-fetal reproduction study in rabbits, skeletal malformations were noted at maternally toxic doses when ketamine was intranasally administered with a No Observed Adverse Effect Level (NOAEL) at estimated esketamine exposures 0.3 times the exposures at the maximum recommended human dose (MRHD) of 84 mg/day. In addition, intranasal administration of esketamine to pregnant rats during pregnancy and lactation at exposures that were similar to those at the MRHD resulted in a delay in sensorimotor development in pups during the preweaning period and a decrease in motor activity in the post-weaning period.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical ConsiderationsDisease-Associated Maternal and/or Embryo-Fetal Risk

A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressants. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

DataAnimal Data

Based on published data, when female monkeys were treated intravenously with racemic ketamine at anesthetic dose levels in the third trimester of pregnancy, neuronal cell death was observed in the brains of their fetuses. This period of brain development translates into the third trimester of human pregnancy. The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits.

Racemic ketamine was administered intranasally to pregnant rats during the period of organogenesis at doses of 15, 50, and 150 mg/kg/day. The No Observed Adverse Effect level (NOAEL) for embryo-fetal toxicity in rats was the highest dose of 150 mg/kg/day. Estimating 50% of the exposure to be from esketamine, the NOAEL associated with esketamine plasma exposure (AUC) is 12-times the AUC exposure at the MRHD of 84 mg/day. In pregnant rabbits, racemic ketamine was administered intranasally from gestational day 6 to 18 at doses of 10, 30, and 100 mg/kg/day. The high dose was lowered from 100 to 50 mg/kg after 5 days of dosing due to excessive mortality in the pregnant rabbits. Skeletal malformations were observed at doses \geq 30mg/kg/day, which were maternally toxic. The NOAEL for skeletal malformations was associated with a plasma esketamine exposure (AUC) that was 0.3 times the AUC exposure at MRHD of 84 mg/day.

Administration of esketamine to pregnant rats during pregnancy and lactation at intranasal doses equivalent to 4.5, 15, and 45 mg/kg/day (based on a 200-gram rat) produced AUC exposures 0.07, 0.5, and 0.7 times the MRHD of 84 mg/day, respectively. Maternal toxicity was observed at doses \geq 15 mg/kg/day. In addition, a dose-dependent delay in the age of attainment of Preyer response reflex was observed in pups at all doses during the preweaning period. This sensory/motor developmental measure was tested starting on postnatal day (PND) 9, and the effect normalized by PND 19 in treatment groups as compared with PND 14 for the majority of the control animals. There is no NOAEL for this delay in sensory/motor response observed in pups during the preweaning period. During the postweaning period, a decrease in motor activity was observed at doses \geq 15 mg/kg which is 0.5-times the human exposure at the MRHD of 84 mg/day. The NOAEL for maternal toxicity and decreased motor activity during the postweaning period was 4.5 mg/kg/day which was associated with a plasma exposure (AUC) that was 0.07-times the AUC exposure at MRHD of 84 mg/day.

LactationRisk Summary

Esketamine is present in human milk. There are no data on the effects of SPRAVATO on the breastfed infant or on milk production. Published studies in juvenile animals report neurotoxicity (see *Data*). Because of the potential for neurotoxicity, advise patients that breast-feeding is not recommended during treatment with SPRAVATO.

Data

Published juvenile animal studies demonstrate that the administration of drugs that block NMDA receptors, such as ketamine, during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but this window may extend out to approximately 3 years of age in humans.

Females and Males of Reproductive PotentialContraception

Based on published animal reproduction studies, SPRAVATO may cause embryo-fetal harm when administered to a pregnant woman [see *Warnings and Precautions and Use in Specific Populations*]. However, it is not clear how these animal findings relate to females of reproductive potential treated with the recommended clinical dose. Consider pregnancy planning and prevention for females of reproductive potential during treatment with SPRAVATO.

Pediatric Use

The safety and effectiveness of SPRAVATO in pediatric patients have not been established. Clinical studies of SPRAVATO in pediatric patients have not been conducted.

Geriatric Use

Of the total number of patients in Phase 3 clinical studies exposed to SPRAVATO, (N=1601), 194 (12%) were 65 years of age and older, and 25 (2%) were 75 years of age and older. No overall differences in the safety profile were observed between patients 65 years of age and older and patients younger than 65 years of age.

The mean esketamine C_{max} and AUC values were higher in elderly patients compared with younger adult patients [see *Clinical Pharmacology (12.3) in Full Prescribing Information*].

The efficacy of SPRAVATO for the treatment of TRD in geriatric patients was evaluated in a 4-week, randomized, double-blind study comparing flexibly-dosed intranasal SPRAVATO plus a newly initiated oral antidepressant compared to intranasal placebo plus a newly initiated oral antidepressant in patients \geq 65 years of age. SPRAVATO was initiated at 28 mg twice weekly

SPRAVATO® (esketamine) nasal spray, CIII

and could be titrated to 56 mg or 84 mg administered twice-weekly. At the end of four weeks, there was no statistically significant difference between groups on the primary efficacy endpoint of change from baseline to Week 4 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Hepatic Impairment

The mean esketamine AUC and $t_{1/2}$ values were higher in patients with moderate hepatic impairment compared to those with normal hepatic function [see *Clinical Pharmacology (12.3) in Full Prescribing Information*]. SPRAVATO-treated patients with moderate hepatic impairment may need to be monitored for adverse reactions for a longer period of time.

SPRAVATO has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Use in this population is not recommended [see *Clinical Pharmacology (12.3) in Full Prescribing Information*].

DRUG ABUSE AND DEPENDENCE

Controlled Substance

SPRAVATO contains esketamine hydrochloride, the (S)-enantiomer of ketamine and a Schedule III controlled substance under the Controlled Substances Act.

Abuse

Individuals with a history of drug abuse or dependence may be at greater risk for abuse and misuse of SPRAVATO. Abuse is the intentional, non-therapeutic use of a drug, even once, for its psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Careful consideration is advised prior to use of individuals with a history of substance use disorder, including alcohol.

SPRAVATO may produce a variety of symptoms including anxiety, dysphoria, disorientation, insomnia, flashback, hallucinations, and feelings of floating, detachment and to be “spaced out”. Monitoring for signs of abuse and misuse is recommended.

Abuse Potential Study

A cross-over, double-blind abuse potential study of SPRAVATO and ketamine was conducted in recreational polydrug users (n=34) who had experience with perception-altering drugs, including ketamine. Ketamine, the racemic mixture of arketamine and esketamine, is a Schedule III controlled substance and has known abuse potential. In this study, the mean “Drug Liking at the Moment” and “Take Drug Again” scores for single doses of intranasal SPRAVATO (84 mg and 112 mg – the maximum recommended dose and 1.3 times the maximum recommended dose, respectively) were similar to these scores in the intravenous ketamine (0.5 mg/kg infused over 40 minutes) control group. However, these scores were greater in the SPRAVATO and ketamine groups compared to the placebo group. The 112 mg dose of intranasal SPRAVATO was associated with significantly higher scores for “Hallucinating,” “Floating,” “Detached,” and “Spaced Out” than the 84 mg dose of intranasal SPRAVATO and the intravenous ketamine dose.

Dependence

Physical dependence has been reported with prolonged use of ketamine. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or significant dosage reduction of a drug. There were no withdrawal symptoms captured up to 4 weeks after cessation of esketamine treatment. Withdrawal symptoms have been reported after the discontinuation of frequently used (more than weekly) large doses of ketamine for long periods of time. Such withdrawal symptoms are likely to occur if esketamine were similarly abused. Reported symptoms of withdrawal associated with daily intake of large doses of ketamine include craving, fatigue, poor appetite, and anxiety. Therefore, monitor SPRAVATO-treated patients for symptoms and signs of physical dependence upon the discontinuation of the drug.

Tolerance has been reported with prolonged use of ketamine. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Similar tolerance would be expected with prolonged use of esketamine.

OVERDOSAGE

Management of Overdosage

There is no specific antidote for esketamine overdose. In the case of overdose, the possibility of multiple drug involvement should be considered. Contact a Certified Poison Control Center for the most up to date information on the management of overdosage (1-800-222-1222 or www.poisson.org).

Manufactured for:

Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560

© 2019 Janssen Pharmaceutical Companies

cp-79820v4

See and Hear What the Field is Discussing



The American Journal of Psychiatry is committed to keeping the field of psychiatry vibrant and relevant by publishing the latest advances in the diagnosis and treatment of mental illness. Here are the most discussed articles that AJP published in the first quarter of 2020 according to Altmetric, which monitors the online mentions and shares of research through daily tracking of 2,000 mainstream media outlets, Wikipedia, citations, social media, and more than 9,000 academic and nonacademic blogs.



Reproducible Genetic Risk Loci for Anxiety: Results From ~200,000 Participants in the Million Veteran Program

Published online: 7 Jan 2020



Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder

February 2020 issue



U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001-2002 and 2012-2013

Published online: 22 Jan 2020



Dive Deeper With AJP Audio

Each episode of the **AJP Audio** podcast brings you an in-depth look at one of the articles featured in that month's issue of *The American Journal of Psychiatry*. Wide-ranging interviews with article authors cover the background, rationale, main findings, and future implications of the research.

- **April 2020: Incidence of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder**

Sarah A. Sullivan, Ph.D., and Stanley Zammit, Ph.D., discuss their research on the incidence, course, and outcome of psychotic experiences from childhood through early adulthood in the general population, and the prediction of psychotic disorder.

- **May 2020: Psychedelics and Psychedelic-Assisted Psychotherapy**

Collin Reiff, M.D., and William McDonald, M.D., discuss their evidence-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders.



Apple Podcasts



Google Podcasts



Spotify



STITCHER™



YouTube



The American Journal of Psychotherapy

psychotherapy.psychiatryonline.org

Holly A. Swartz, M.D., Editor-in-Chief

The American Journal of Psychotherapy is a peer-reviewed, interdisciplinary journal published quarterly by the American Psychiatric Association. Begun in 1947 by the Association for the Advancement of Psychotherapy, *The American Journal of Psychotherapy* provides a forum for advancing the theory, science, and clinical practice of psychotherapy, publishing articles that expand the understanding of psychotherapies, especially in the domains of efficacy, process, education, and practice.

The journal publishes empirical papers on psychotherapy outcomes, process, measurement, and education. Maintaining a strong clinical focus, it welcomes case reports, review articles, and training tools that will guide and shape clinical practice.

The American Journal of Psychotherapy invites a broad range of perspectives from all psychotherapy disciplines, including but not limited to psychodynamic, interpersonal, cognitive- or dialectical-behavioral, existential, emotion-focused, problem-solving, mentalizing, mindfulness-based, and client-centered approaches.

The American Journal of Psychotherapy inclusively addresses topics across treatment modalities, age groups, genders, races and ethnicities, and diagnoses. The journal serves the international community by curating a vibrant, pluralistic, dialogue about psychotherapy that ultimately will inform clinical care.



2018 • Vol. 73
Frequency: Quarterly
Online ISSN: 2575-6559
psychotherapy.psychiatryonline.org

Subscribe Now!

 ***Visit appi.org for pricing and more information!***

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



appi.org
1-800-368-5777
appi@psych.org

psychotherapy.psychiatryonline.org

AH2005A

The American Psychiatric Association Publishing Textbook of Schizophrenia, Second Edition

Edited by Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H.,
Diana O. Perkins, M.D., M.P.H., and Lisa B. Dixon, M.D., M.P.H.

Schizophrenia is one of the leading causes of disability worldwide and remains among the most challenging and disheartening disorders confronting psychiatrists and other mental health care providers because of its profound effects on patient functioning, its onset just as young adults are launching their lives, and the limitations of current pharmacological treatments.

Designed to bring the reader up to date on the latest research, this new edition represents a complete overhaul of the previous text, with a new structure, new chapters, and new contributors.

Subjects such as genetics and neurobiology, distinguished by rapid advancements in knowledge, are explored in depth, as are new models of service delivery and psychosocial treatments that are making a significant difference in patients' lives. Foundational information on the epidemiology, etiology, and psychopathology of the illness is presented clearly and cogently, emphasizing research conducted over the last decade. Theories regarding the pathophysiological basis of the disorder, including genetic, molecular, and neurocircuitry models, are examined in detail.


Other noteworthy topics include

- Cultural variations, examining how culture influences the presentation of schizophrenia from the perspective of the experts in cultural psychiatry who developed the DSM-5 Cultural Formulation Interview
- Service delivery models, including assertive community treatment, critical time intervention, coordinated specialty care for early psychosis, and integrated dual diagnosis
- Advances in the existing pharmacological treatments, including use of adjunctive medications and combinations of antipsychotics, which, in the absence of new drug therapies, is indispensable knowledge
- A review of the promising field of neuromodulation
- Evaluation and treatment of comorbidities
- Individual- and family-centered care, which presents the rationale and evidence for actively involving patients and family members in interventions and decision-making about treatments

Designed for ease of use, *The American Psychiatric Association Publishing Textbook of Schizophrenia* furnishes evidence-based and cutting-edge knowledge for the next generation of students, trainees, and clinicians.

2020 • 336 pages • ISBN 978-1-61537-172-3 • Hardcover • \$140.00 • Item #37172

2020 • 336 pages • ISBN 978-1-61537-291-1 • eBook • \$112.00 • Item #37291



★ 20% Discount for American Psychiatric Association Members
25% Discount for APA Resident-Fellow Members

ORDER @ www.appi.org | Email: appi@psych.org | Toll Free: 1-800-368-5777

THE AMERICAN PSYCHIATRIC ASSOCIATION

800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024

(888) 357-7924 (toll-free inside the U.S. and Canada)

web site: www.psychiatry.org • e-mail: apa@psych.org

Chairpersons of Councils, Committees, and Task Forces

Standing Committees

Bylaws	Kimberly D. Nordstrom, M.D., J.D.
Elections	Justin W. Schoen, M.D.
Ethics	Rebecca W. Brendel, M.D., J.D.
Finance and Budget	Ann T. Sullivan, M.D.
<i>Audit</i>	Ayana Jordan, M.D., Ph.D.
<i>Investment Oversight</i>	Steven S. Sharfstein, M.D.
Joint Reference	Vivian Pender, M.D.
Membership	Eric R. Williams, M.D.
Nominating	Bruce J. Schwartz, M.D.
Tellers	John A. Talbott, M.D.

Non-Standing Committee

Conflict of Interest	Sandra M. DeJong, M.D., M.Sc.
-----------------------------	-------------------------------

Councils

Council on Addiction Psychiatry

Jill Williams, M.D.

Council on Advocacy and Government Relations

Katherine G. Kennedy, M.D.

Advocacy and Litigation Funding

Bhasker J. Dave, M.D.

Council on Children, Adolescents, and Their Families

Gabrielle Shapiro, M.D.

Women's Mental Health

Ludmila B. De Faria, M.D.

Council on Communications

Isabel K. Norian, M.D.

Council on Consultation-Liaison Psychiatry

Sejal B. Shah, M.D.

Council on Geriatric Psychiatry

Robert P. Roca, M.D.

Council on Healthcare Systems and Financing

Robert L. Trestman, M.D., Ph.D.

Integrated Care

Henry Chung, M.D.

RBRVS, Codes and Reimbursement

Gregory G. Harris, M.D.

Reimbursement for Psychiatric Care

Laurence H. Miller, M.D.

Telepsychiatry

James H. Shore, M.D.

Council on International Psychiatry

David C. Henderson, M.D.

Chester Pierce Human Rights Award Committee

[Pending]

Council on Medical Education and Lifelong Learning

Eindra Khin Khin, M.D.

Innovation

Nina Vasani, M.D.

Scientific Program

Jacqueline M. Feldman, M.D.

Scientific Program-IPS (Oct. to Oct. tenure)

[Pending]

Vestermark Award Committee

Joseph A. Cheong, M.D.

Well-being and Burnout

Batool Kazim, M.D.

Council on Minority Mental Health and Health Disparities

Eric Yarbrough, M.D.

Council on Psychiatry and Law

Debra A. Pinals, M.D.

Judicial Action

Reena Kapoor, M.D.

Council on Quality Care

Grayson S. Norquist, M.D.

Mental Health Information Technology

John Torous, M.D.

Quality and Performance Measurement

Carol Alter, M.D.

Practice Guidelines

Daniel J. Anzia, M.D.

Council on Research

Jonathan E. Alpert, M.D., Ph.D.


Psychiatric Dimensions of Disasters

Joshua C. Morganstein, M.D.

The American Psychiatric Association Publishing Textbook of Suicide Risk Assessment and Management, Third Edition

Edited by Liza H. Gold, M.D., and Richard L. Frierson, M.D.

Charged with updating the preeminent text on suicide, the new editors of *The American Psychiatric Association Publishing Textbook of Suicide Risk Assessment and Management* opted not to simply revise existing chapters, but instead to steer a bold course, expanding, reconfiguring, and remaking the third edition to reflect the latest research, nomenclature, and clinical innovations. The editorial team and contributors—two-thirds of whom are new to this edition—have taken the intersection of suicide with both mental health and psychosocial issues as their organizing principle, exploring risk assessment and epidemiology in special populations, such as elderly patients, college students, military personnel, and the incarcerated as well as patients with a variety of psychological disorders, including bipolar spectrum, personality, depressive, anxiety, posttraumatic stress, and other disorders and schizophrenia. In addition, the book discusses treatment options (such as cognitive-behavioral therapy, dialectical behavioral therapy, and pharmacotherapy) and settings (such as emergency services, outpatient, inpatient, and civil commitment) in detail, with clinical cases to contextualize the material.



The new and revised content is extensive:

- A chapter on the influence of sleep and sleep disorders on suicide risk has been included that considers possible mechanisms for this link and discusses practical ways of assessing and managing sleep disorders to mitigate suicide risk.
- Nonsuicidal self-injury, the prevalence of which is particularly high among youth, is addressed in detail, differentiating it from and comparing it to suicide attempts, discussing risk assessment, considering safety interventions, examining treatment options, and exploring suicide contagion.
- No text on suicide would be complete without a serious exploration of the role of social media and the internet. The book presents an update on current research as it pertains to social networking and behavior, information access, and artificial intelligence and software, and includes suggestions for clinicians treating patients at risk for suicide.

Its diverse range of perspectives, broad relevance to a wide variety of clinicians, and absolutely authoritative coverage makes this new edition of *The American Psychiatric Association Publishing Textbook of Suicide Risk Assessment and Management* a worthy and indispensable successor.

2020 • 477 pages • ISBN 978-1-61537-223-2 • Hardcover • \$120.00 • Item #37223

2020 • 477 pages • ISBN 978-1-61537-284-3 • eBook • \$96.00 • Item #37284



★ 20% Discount for American Psychiatric Association Members
25% Discount for APA Resident-Fellow Members

ORDER @ www.appi.org | Email: appi@psych.org | Toll Free: 1-800-368-5777

Go Online

Visit ajp.psychiatryonline.org for these features!

AJP in Advance *Discover the latest research advances before they appear in print*
Brain Reward System Dysfunction in Adolescence: Current, Cumulative, and Developmental Periods of Depression

Longitudinal research that utilizes brain-imaging methods provides important information on neurodevelopmental aspects of psychopathology. The authors here used longitudinal data on a sample tracked for mood symptoms since preschool and examined relations between the course of depressive symptoms and neural correlates of reward processing. The data suggest that the timing of depressive symptoms across child development predicts patterns of reward-system dysfunction.

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression

There is a particular need for new therapies in the area of treatment-resistant major depressive disorder. The authors studied a variant of intermittent theta-burst stimulation as a novel therapy for the condition; stimulation was guided using data from brain imaging with each patient. The study lays the groundwork for more definitive evaluations of this novel therapy.

AJP CME *Earn CME credit: 3 courses per issue*

This month's courses appear on pages 643–646.

Each short course is based on one article in this issue and can earn up to 1 *AMA PRA Category 1 Credit™*. CME credit is issued only **online**, and a paid subscription to AJP's CME course program is required.

Visit psychiatryonline.org/cme and click on the "American Journal of Psychiatry" tab.

AJP Multimedia *Access Audio for highlights of each issue*

In AJP Audio this month, Executive Editor Michael Roy speaks with Stéphane Potvin, Ph.D., and Alexandre Dumais, M.D., Ph.D., about their research on the extent to which cannabis use among youths is associated with the risk of perpetrating physical violence (p. 619).

History of Psychiatry *Revisit the field's rich history through the AJP Archive*

175 years ago this month: Asylums in an Enlightened Age

Two of the "13 Founders" of the organization that became today's American Psychiatric Association present their views on how asylums in the United States should be built and run. Pliny Earle provides a historical and descriptive account of his Bloomingdale Asylum for the Insane, while Luther V. Bell describes modern improvements in the construction, ventilation, and warming of buildings.

Note
Our New
Twitter
Handle!

@APAPubJournals



Psychiatry Online



AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
1-800-368-5777
appi@psych.org